Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10
This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors.
Patent Number
US 11499167
Status
Active
Filing Date
October 12, 2021
Grant Date
November 15, 2022
Expiration
October 12, 2041
Claims
20
Assignee
University of Pennsylvania
Inventors
James M. Wilson, Mauricio R. Alvira, Guangping Gao
Citations
0 forward · 86 backward
What it covers
The patent claims a "cultured host cell" that has been genetically modified. This cell contains a "recombinant nucleic acid molecule" (an engineered piece of DNA) that carries instructions for two main things: first, making specific parts of the AAVrh.10 virus, such as its "vp1 capsid protein" (amino acids 1 to 738 of SEQ ID NO: 81), or vp2, or vp3, or specific nucleotide sequences (like 845 to 3058 of SEQ ID NO: 59); and second, a "heterologous non-AAV sequence." This "heterologous" part is the therapeutic genetic material that a gene therapy aims to deliver. For example, a cell could be engineered to produce the outer shell of the AAVrh.10 virus, while also carrying the gene for a missing protein in a patient. Some claims also specify the presence of a "functional rep gene" (which helps the virus replicate) and that the recombinant molecule can be a "plasmid" (a common way to introduce DNA into cells).
What it doesn't cover
- —Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.
- —Does not cover host cells containing AAVrh.10 components without an additional "heterologous non-AAV sequence."
- —Does not cover other types of adeno-associated viruses (AAVs) beyond the specific AAVrh.10 variant described.
- —Does not cover gene therapy vectors that use entirely different viral or non-viral delivery systems.
- —Does not cover cells containing only the AAV 'rep gene' without the specified capsid protein or nucleotide sequences.
The clever bit
The novelty lies in precisely defining and claiming the use of specific AAVrh.10 capsid protein sequences (like VP1, VP2, VP3 from SEQ ID NO: 81) or specific nucleic acid sequences (from SEQ ID NO: 59) within a cultured host cell, specifically combined with a "heterologous non-AAV sequence" for gene delivery applications. This focuses on a particular, potentially advantageous, AAV serotype for vector production.
Why it matters
Adeno-associated viruses (AAVs) are widely used in gene therapy because they can deliver genetic material into cells safely and efficiently. The University of Pennsylvania, particularly through Dr. James Wilson's lab, has been a pioneer in identifying and developing different AAV serotypes, like AAVrh.10, which can have unique properties for targeting specific tissues or evading immune responses. This patent protects the specific engineering of cells to produce gene therapy vectors using this particular AAVrh.10 variant, which is crucial for developing new treatments for genetic diseases.
Real-world examples
- 1.Manufacturing of gene therapy vectors in bioreactors
- 2.Research into new gene therapies for genetic disorders
- 3.Production of AAV-based vaccines in laboratory settings
Generated by PatentBrief · Not legal advice · patentbrief.org
US 11499167 · 2026